Relapsed Multiple Myeloma

Oncology
15
Pipeline Programs
7
Companies
7
Clinical Trials
8
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
2
0
3
8
Early DiscoveryClinical DevelopmentMarket

On Market (8)

Approved therapies currently available

U
DEXAMETHASONEApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]oral2024
U
DEXONE 0.5Approved
dexamethasone
Unknown Company
oral
U
DEXONE 0.75Approved
dexamethasone
Unknown Company
oral
U
DEXONE 1.5Approved
dexamethasone
Unknown Company
oral1975
U
DEXONE 4Approved
dexamethasone
Unknown Company
oral
U
DEXYCU KITApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]intraocular2018
U
MAXIDEXApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]ophthalmic1962
Takeda
NINLAROApproved
ixazomib
Takeda
oral2015

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
1
IxazomibPhase 31 trial
Active Trials
NCT01564537Completed722Est. Feb 2022
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
DexamethasonePhase 31 trial
Active Trials
NCT03158688Completed466Est. Apr 2022
Oncopeptides
OncopeptidesSweden - Stockholm
1 program
1
MelflufenPhase 31 trial
Active Trials
NCT04649060TerminatedEst. Feb 2022
CASI Pharmaceuticals
CASI PharmaceuticalsBEIJING, China
1 program
1
2-methoxyestradiolPhase 21 trial
Active Trials
NCT00592579CompletedEst. Sep 2008
Karyopharm Therapeutics
1 program
1
Elotuzumab, Selinexor, and DexamethasonePhase 21 trial
Active Trials
NCT05170789WithdrawnEst. Apr 2022
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
REGN5459Phase 1/21 trial
Active Trials
NCT04083534Completed43Est. May 2025
Ionis Pharmaceuticals
1 program
1
ION251Phase 11 trial
Active Trials
NCT04398485Completed23Est. Sep 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OncopeptidesMelflufen
AmgenDexamethasone
TakedaIxazomib
Karyopharm TherapeuticsElotuzumab, Selinexor, and Dexamethasone
CASI Pharmaceuticals2-methoxyestradiol
RegeneronREGN5459
Ionis PharmaceuticalsION251

Clinical Trials (7)

Total enrollment: 1,254 patients across 7 trials

NCT04649060OncopeptidesMelflufen

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

Start: Dec 2020Est. completion: Feb 2022
Phase 3Terminated
NCT03158688AmgenDexamethasone

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Start: Jun 2017Est. completion: Apr 2022466 patients
Phase 3Completed
NCT01564537TakedaIxazomib

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Start: Aug 2012Est. completion: Feb 2022722 patients
Phase 3Completed
NCT05170789Karyopharm TherapeuticsElotuzumab, Selinexor, and Dexamethasone

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

Start: Apr 2022Est. completion: Apr 2022
Phase 2Withdrawn
NCT00592579CASI Pharmaceuticals2-methoxyestradiol

A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma

Start: Mar 2001Est. completion: Sep 2008
Phase 2Completed
NCT04083534RegeneronREGN5459

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

Start: Sep 2019Est. completion: May 202543 patients
Phase 1/2Completed
NCT04398485Ionis PharmaceuticalsION251

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

Start: Jan 2021Est. completion: Sep 202423 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
3m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
13m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
17m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
17m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)